Amylyx Pharmaceuticals
43 Thorndike Street
Cambridge
MA
02141
United States
Tel: 781-249-9052
Website: https://www.amylyx.com/
103 articles with Amylyx Pharmaceuticals
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
3/13/2023
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
3/8/2023
Amylyx Pharmaceuticals, Inc. will participate in the following upcoming investor conferences, which are being conducted in a virtual format.
-
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
3/7/2023
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, following the close of the U.S. financial markets.
-
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
2/7/2023
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the SVB Securities Global Biopharma Conference.
-
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
2/2/2023
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the completion of enrollment in PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) in people living with amyotrophic lateral sclerosis (ALS).
-
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
-
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
11/22/2022
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference.
-
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/10/2022
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.
-
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
11/3/2022
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced it will report third quarter 2022 financial results on Thursday, November 10, 2022 following the close of the U.S. financial markets.
-
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
10/11/2022
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price of $32.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,004,062 shares of common stock in the offering.
-
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - October 07, 2022
10/7/2022
Amylyx Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00 per share.
-
Amylyx plans to offer 6 million shares in a public offering to bring in between $167 to $192.2 million to support the manufacturing and commercialization of recently approved ALS drug Relyvrio.
-
Amylyx Pharmaceuticals Announces Launch of Public Offering
10/4/2022
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”).
-
The FDA’s approval of Amylyx's Relyvrio has ignited the growing momentum in the ALS space. BioSpace spoke with Amylyx co-CEOs Justin Klee and Josh Cohen and leading ALS researcher Dr. Merit Cudkowicz.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
The biopharma world - and markets - spent Thursday evening reacting after the FDA gave the green light to only its third-ever drug for ALS, Amylyx's Relyvrio.
-
FDA Approves New Treatment Option for Patients with ALS
9/29/2022
The U.S. Food and Drug Administration approved Relyvrio to treat patients with amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig's disease.
-
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
9/29/2022
Amylyx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved RELYVRIO™ for the treatment of adults with amyotrophic lateral sclerosis.
-
The FDA might only have two PDUFA dates on the calendar this week, but all eyes in the neurodegenerative disease community will be on the first one: Amylyx's AMX0035 for ALS.
-
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
9/14/2022
Amylyx Pharmaceuticals, Inc. today announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial that evaluated the safety, efficacy, and survival benefits of AMX0035 in adult participants with amyotrophic lateral sclerosis (ALS) are now available in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.